TY - JOUR
T1 - Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series
AU - Bosma, A. L.
AU - Gerbens, L. A. A.
AU - Middelkamp-Hup, M. A.
AU - Spuls, P. I.
N1 - Funding Information: This case series was partly funded by a government grant through the Rational Pharmacotherapy programme of ZonMw, The Netherlands Organization for Health Research and Development. Funding Information: This case series was partly funded by a government grant through the Rational Pharmacotherapy programme of ZonMw, The Netherlands Organization for Health Research and Development. AB and LG have no conflicts of interest to declare. MAM has performed consultancies for Sanofi and Pfizer. PS has performed consultancies in the past for Sanofi 111017 and AbbVie 041217 (unpaid), has received independent research grants in the past > 5 years ago, and has provided contract support, including involvement in performing clinical trials, to many pharmaceutical industries that manufacture drugs used for the treatment of diseases such as psoriasis and atopic dermatitis, for which financial compensation is paid to the hospital. Learning points AD is a chronic, pruritic inflammatory skin disorder that affects patients of reproductive age and can worsen during pregnancy. There is a lack of knowledge about treatment with dupilumab during conception in both men and women, as well as during pregnancy and lactation in women. We present four uncomplicated cases in two men with AD who conceived during dupilumab treatment and two women with AD who discontinued dupilumab because of anticipated pregnancy. An overview of the current evidence in the literature is given to guide considerations for patients on dupilumab wishing to conceive a child. Preference is given to treatment with topical corticosteroids, phototherapy, systemic corticosteroids and ciclosporin, instead of dupilumab, until more data are available. We recommend that dupilumab treatment during pregnancy and lactation should be investigated in large cohort studies. AD is a chronic, pruritic inflammatory skin disorder that affects patients of reproductive age and can worsen during pregnancy. There is a lack of knowledge about treatment with dupilumab during conception in both men and women, as well as during pregnancy and lactation in women. We present four uncomplicated cases in two men with AD who conceived during dupilumab treatment and two women with AD who discontinued dupilumab because of anticipated pregnancy. An overview of the current evidence in the literature is given to guide considerations for patients on dupilumab wishing to conceive a child. Preference is given to treatment with topical corticosteroids, phototherapy, systemic corticosteroids and ciclosporin, instead of dupilumab, until more data are available. We recommend that dupilumab treatment during pregnancy and lactation should be investigated in large cohort studies. Publisher Copyright: © 2021 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/8
Y1 - 2021/8
N2 - Dupilumab is a relatively new treatment option for patients with moderate to severe atopic dermatitis. There is a lack of knowledge about the effects of treatment with dupilumab during conception for both men and women, as well as during pregnancy and lactation in women. We report four patients (two men, two women) who expressed a wish to conceive during treatment with dupilumab in daily practice. Both men conceived during dupilumab treatment, while the two women discontinued dupilumab because of anticipated pregnancy. Apart from disease flares in both of the patients who discontinued treatment, no complications were reported concerning the ability to conceive, the course of the pregnancy or the fetal outcome. We present an overview of the current available literature on dupilumab during conception, pregnancy and lactation, which can guide considerations for patients on dupilumab wishing to conceive a child. Until more data are available, preference should be given to treatment with topical corticosteroids, phototherapy, systemic corticosteroids and ciclosporin.
AB - Dupilumab is a relatively new treatment option for patients with moderate to severe atopic dermatitis. There is a lack of knowledge about the effects of treatment with dupilumab during conception for both men and women, as well as during pregnancy and lactation in women. We report four patients (two men, two women) who expressed a wish to conceive during treatment with dupilumab in daily practice. Both men conceived during dupilumab treatment, while the two women discontinued dupilumab because of anticipated pregnancy. Apart from disease flares in both of the patients who discontinued treatment, no complications were reported concerning the ability to conceive, the course of the pregnancy or the fetal outcome. We present an overview of the current available literature on dupilumab during conception, pregnancy and lactation, which can guide considerations for patients on dupilumab wishing to conceive a child. Until more data are available, preference should be given to treatment with topical corticosteroids, phototherapy, systemic corticosteroids and ciclosporin.
UR - http://www.scopus.com/inward/record.url?scp=85107200883&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/ced.14725
DO - https://doi.org/10.1111/ced.14725
M3 - Article
C2 - 33969522
SN - 0307-6938
VL - 46
SP - 1089
EP - 1092
JO - Clinical and experimental dermatology
JF - Clinical and experimental dermatology
IS - 6
ER -